PE20000013A1 - Derivados de adenosina - Google Patents

Derivados de adenosina

Info

Publication number
PE20000013A1
PE20000013A1 PE1998001065A PE00106598A PE20000013A1 PE 20000013 A1 PE20000013 A1 PE 20000013A1 PE 1998001065 A PE1998001065 A PE 1998001065A PE 00106598 A PE00106598 A PE 00106598A PE 20000013 A1 PE20000013 A1 PE 20000013A1
Authority
PE
Peru
Prior art keywords
adenosine
disease
receptor
alkyl
deoxy
Prior art date
Application number
PE1998001065A
Other languages
English (en)
Spanish (es)
Inventor
Colin David Eldred
Richard Peter Charles Cousins
Andrew Michael Kenneth Pennell
Brian Cox
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20000013A1 publication Critical patent/PE20000013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE1998001065A 1997-11-08 1998-11-05 Derivados de adenosina PE20000013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20000013A1 true PE20000013A1 (es) 2000-01-21

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001065A PE20000013A1 (es) 1997-11-08 1998-11-05 Derivados de adenosina

Country Status (29)

Country Link
US (1) US6455510B1 (enExample)
EP (2) EP1030857B1 (enExample)
JP (1) JP2001522857A (enExample)
KR (1) KR20010031875A (enExample)
CN (1) CN1285843A (enExample)
AP (1) AP2000001801A0 (enExample)
AR (1) AR011229A1 (enExample)
AT (1) ATE273990T1 (enExample)
AU (1) AU2048399A (enExample)
BR (1) BR9813976A (enExample)
CA (1) CA2309200A1 (enExample)
CO (1) CO5021135A1 (enExample)
DE (1) DE69825780T2 (enExample)
EA (1) EA200000392A1 (enExample)
EE (1) EE200000285A (enExample)
ES (1) ES2222621T3 (enExample)
GB (1) GB9723589D0 (enExample)
HR (1) HRP20000275A2 (enExample)
HU (1) HUP0004082A2 (enExample)
IL (1) IL135964A0 (enExample)
IS (1) IS5477A (enExample)
MA (1) MA26565A1 (enExample)
NO (1) NO20002361L (enExample)
PE (1) PE20000013A1 (enExample)
PL (1) PL340921A1 (enExample)
SK (1) SK6722000A3 (enExample)
TR (1) TR200002131T2 (enExample)
WO (1) WO1999024449A2 (enExample)
ZA (1) ZA9810125B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシン受容体の部分および完全アゴニスト
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1794162A1 (en) * 2004-09-09 2007-06-13 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Purine derivatives as a3 and a1 adenosine receptor agonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
IL321433A (en) 2022-12-16 2025-08-01 Astrazeneca Ab Purines 2,6,9 trimethylated

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
AU2022597A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2048399A (en) 1999-05-31
EE200000285A (et) 2001-08-15
DE69825780D1 (de) 2004-09-23
CN1285843A (zh) 2001-02-28
WO1999024449A2 (en) 1999-05-20
NO20002361D0 (no) 2000-05-05
HUP0004082A2 (hu) 2001-04-28
AP2000001801A0 (en) 2000-06-30
NO20002361L (no) 2000-07-05
TR200002131T2 (tr) 2001-01-22
ZA9810125B (en) 2000-05-05
EA200000392A1 (ru) 2000-12-25
ATE273990T1 (de) 2004-09-15
DE69825780T2 (de) 2005-01-13
IS5477A (is) 2000-05-03
AR011229A1 (es) 2000-08-02
WO1999024449A3 (en) 1999-08-19
EP1030857A2 (en) 2000-08-30
BR9813976A (pt) 2000-09-26
JP2001522857A (ja) 2001-11-20
PL340921A1 (en) 2001-03-12
EP1030857B1 (en) 2004-08-18
CO5021135A1 (es) 2001-03-27
HRP20000275A2 (en) 2000-12-31
IL135964A0 (en) 2001-05-20
GB9723589D0 (en) 1998-01-07
MA26565A1 (fr) 2004-12-20
US6455510B1 (en) 2002-09-24
KR20010031875A (ko) 2001-04-16
EP1457495A1 (en) 2004-09-15
CA2309200A1 (en) 1999-05-20
ES2222621T3 (es) 2005-02-01
SK6722000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
PE20000013A1 (es) Derivados de adenosina
PE20001485A1 (es) Derivados de la camptotecina que tienen actividad antitumoral
PE20000704A1 (es) Derivados de adenosina
KR940007021A (ko) 흥분성 아미노산 수용체 길항물질
PE46899A1 (es) Derivados de n-fenil-sulfonamida
LU91073I2 (fr) EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA)
KR880011125A (ko) 헤테로 싸이클릭 화합물, 그의 제조방법 및 용도
PT1178045E (pt) Derivados de azaindole-etilamina como agentes de ligacao de receptores de acetilcolina nicotinicos
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
AR015238A1 (es) PROCESO PARA LA PREPARACIoN DE ETERES AMINICOS ESTERICAMENTE IMPEDIDOS, COMPOSICIONES, COMPUESTOS Y USO DE DICHOS COMPUESTOS COMO ESTABILIZANTES O RETARDANTES DE LLAMA, Y PROCESO PARA ESTABILIZAR UN MATERIAL ORGÁNICO
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
SE8505715L (sv) Indolderivat
RU94019425A (ru) Производные изатиноксима, способ их получения, фармацевтическая композиция и способ лечения
PE130999A1 (es) 4-oxo-naftiridin-3-carboxamidas sustituidas; ligandos de receptor cerebral gaba
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
RU2005100761A (ru) Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов
NO164593C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbamat- eller urea-derivater.
KR850007600A (ko) 테트라히드로티에노피리딘의 제조방법
MX9305300A (es) Nuevos derivados de 3-oxadiazolil-1-6-naftiridina y proceso para supreparacion.
KR880009943A (ko) 피리다지논 유도체
KR950031072A (ko) 새로운 3- 벤조일-3, 7-디아자바이사이클로[3, 3, 1]노난-화합물을 함유하는 약제
GB1354451A (en) Halogen-substituted phenyl-alkylamines and their derivatives

Legal Events

Date Code Title Description
FC Refusal